Peripheral neuropathies are a frequent and serious consequence of chemotherapy. AEG33783 is a neuroprotective Clin. Development candidate that protects primary SCG neurons from apoptosis induced by NGF withdrawal and from treatment with anti-cancer agents. Animal models utilizing paclitaxel, cisplatin or oxaliplatin demonstrated that AEG33783 attenuates the damaging effects of CT agents on nerve conduction velocity, without interfering with cancer chemotherapy, or affecting the pharmacokinetic profile of a co-administered chemotherapy. AEG33783 displays dose linearity pharmacokinetics with rapid tissue distribution. AEG33783 blocks apoptotic responses of neurons to chemotherapeutic stress by indirectly inhibiting the JNK pathway through HSP70 induction. In vivo analyses confirm these effects, showing that AEG33783 induces HSP70 expression in sciatic nerve, and attenuates cyclin D1 expression in dorsal root ganglia (DRG) neurons in response to cisplatin. AEG33783 represents a novel therapeutic strategy for the treatment of chemotherapy induced neuropathy.